SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-026357
Filing Date
2018-01-31
Accepted
2018-01-31 07:17:03
Documents
6
Period of Report
2018-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d435214d8k.htm 8-K 31358
2 EX-2.1 d435214dex21.htm EX-2.1 486835
3 EX-3.1 d435214dex31.htm EX-3.1 2503
4 EX-99.1 d435214dex991.htm EX-99.1 25971
5 GRAPHIC g519414untitled.jpg GRAPHIC 6656
6 GRAPHIC g519414untitleda.jpg GRAPHIC 7900
  Complete submission text file 0001193125-18-026357.txt   568484
Mailing Address 3101 WESTERN AVE. SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVE. SUITE 600 SEATTLE WA 98121 (206) 801-2100
Cascadian Therapeutics, Inc. (Filer) CIK: 0001412067 (see all company filings)

IRS No.: 260868560 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33882 | Film No.: 18560985
SIC: 8731 Services-Commercial Physical & Biological Research